PureTech Health (LON:PRTC)‘s stock had its “buy” rating restated by equities research analysts at Liberum Capital in a research report issued on Thursday, ThisIsMoney.Co.Uk reports.
A number of other research analysts have also recently commented on PRTC. Peel Hunt reissued a “buy” rating on shares of PureTech Health in a research report on Thursday, January 24th. Jefferies Financial Group reissued a “buy” rating and set a GBX 255 ($3.33) target price on shares of PureTech Health in a research report on Thursday, March 7th.
LON PRTC opened at GBX 197.50 ($2.58) on Thursday. PureTech Health has a 52 week low of GBX 135 ($1.76) and a 52 week high of GBX 215 ($2.81). The company has a debt-to-equity ratio of 7.19, a quick ratio of 0.95 and a current ratio of 0.98. The firm has a market cap of $557.93 million and a PE ratio of -12.34.
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Read More: Why do companies pay special dividends?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.